Experimental cell combo shows early safety in tough lung cancer
Disease control
Completed
This early-stage study tested whether adding PB101 (a patient's own immune cells) to standard targeted therapy (EGFR-TKI) is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was …
Phase: PHASE1 • Sponsor: Precision Biotech Taiwan Corp. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC